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HCV-Ag-speciﬁc TH17 cells secrete IL17, a cytokine involved in autoimmune diseases and regulated by IL10 and TGF-b. 5–12% of
patients with chronic HCV infection have hypothyroidism. We evaluated therole of these cytokines in this patients by determining
serum concentration of TsH, T3, free T4, IL2, IL10, IL12, IL17, TGF-b, anti-TG, TPO, CCP, GBM, and cardiolipin antibodies in 87
chronically noninterferon treated HCV-infected patients. 20 patients (group A) had elevated TsH values (>5μUI/ml) whereas the
remaining 67 (group B) had normal values. The percentage of anti-TPO, TG, GBM, and cardiolipin antibodies in group A patients
(33%, 41%, 5% and 5%, resp.) as well as IL17, IL2 and TGF-b concentrations (25 ± 23 pg/ml, 643 ± 572 pg/ml, and 618 ± 221
pg/ml, resp.) were signiﬁcantly higher than group B. Abnormal Th17 regulation mediated by IL-2 and low TGF-b concentrations
is associated with hypothyroidism in chronically-infected HCV patients.
1.Introduction
There is ample evidence showing that 7–11% of HCV-
infectedchildrenandadultindividualshavethyroiddysfunc-
tion, mainly subclinical hypothyroidism, prior to the initi-
ation of treatment [1, 2]. The association between autoim-
mune thyroiditis in HCV-infected patients, in particular
in subjects with HCV-related mixed cryoglobulinemia, has
also been conﬁrmed [3]. Once combined pegIFNalpha2b +
ribavirin therapy is initiated, the percentage of patients with
thyroid dysfunction goes up to 15–20% [4]. Immunological
mechanisms at the origin of this thyroid dysfunction are
presumed but the precise mechanism still is unknown.
IL-17A, a proinﬂammatory cytokine, is secreted by the
CD4+Th17 cells [5]. It is involved in some organ-speciﬁc
autoimmune diseases such as rheumatoid arthritis, asthma,
inﬂammatory bowel disease, multiple sclerosis, and even
organ allograft rejection [6–9], among many others. The
main function of IL-17-secreting T cells is to mediate
inﬂammation, by stimulating production of inﬂammatory
cytokines, such as TNF-a, IL-1b, IL-6, and inﬂammatory
chemokinesthatpromotetherecruitmentofneutrophilsand
macrophages [10]. Initial evidence suggested that human
Th17 cells were regulated by CD4+25+FoxP3+ regulatory
T cells, but recent evidence suggests an alternative regula-
tory mechanism mediated by IL-10 and TGF-b [11, 12].2 Hepatitis Research and Treatment
Ag-speciﬁc Th17 cells are induced in HCV-infected patients,
but the HCV-NS4 protein also induces the secretion of IL-10
and TGF-b by monocytes [13]. Neutralization of both anti-
inﬂammatory cytokines signiﬁcantly enhances NS4-speciﬁc
IL-17 and IFN-gamma production by T cells from HCV-
infected donors [14]. Although this may represent a novel
immune subversion mechanism by the virus to evade host
protective immune responses, it could also be responsible
for the thyroid dysfunction. The precise mechanisms of such
dysfunction remain obscure.
An initial evaluation of the thyroid function in chroni-
cally infected HCV patients referred to the Gastroenterology
Service at Mexico’s H.R. “Lic. Adolfo Lopez Mateos”, ISSSTE,
showed that a high percentage of patients had subclinical
hypothyroidism prior to the initiation of combined treat-
ment. Therefore, our aim was to evaluate the serological
status of IL-10, TGF-b and IL-17 in chronically non-
interferon treated HCV-infected patients with or without
subclinical hypothyroidism.
2.MaterialandMethods
2.1. Patients. Eighty seven patients attending an HCV out-
patient clinic at HR “Lic. Adolfo Lopez Mateos”, ISSSTE,
Mexico, were recruited for this study. Written informed
consent was obtained from each patient. The study was
approved by the local Research and Ethics Committee.
All patients tested positive for antibodies to HCV using
an enzyme immunoassay (Abbott Diagnostics). They were
all infected as determined by consistently positive HCV
RNA serum detection results using a qualitative RT-PCR
(Amplicor; Roche Diagnostic Systems). None of the patients
(25 males and 62 females) had ever received treatment with
pegylated interferon and/or ribavirin. Their mean age was
50.1 years old (31–69). A single experienced histopathologist
scored liver biopsy specimens from all the patients. All the
patients were catalogued as a class A Child-Pugh score and
were selected to initiate pegylated interferon treatment. The
control group was conformed by 40 individuals (20 males,
20 females; with a mean age of 48 years old) with no history
of liver disease, negative to HCV antibodies and normal liver
function tests.
2.2.BiochemicalParameters. Bloodsamples,freshlyobtained
from each patient one week before treatment was initiated,
stood for 5 minutes at room temperature before being
centrifuged for 10 minutes at 1800rpm at 4◦C. Plasma
and sera was obtained from each patient and aliquots of
0.1ml were kept at −70◦C until use. Plasma levels of IL-
2, IL-10, IL-12, IL-17, and TGF-b were determined using
commercially available kits purchased from Genzyme and
R & D systems (Quantikine) carefully following the manu-
facturer instructions. The R value for the linear regression
of the standard curve had to be 0.95 or higher, a lower
value was considered inadequate and the data obtained of
such plates was eliminated. In order to activate latent TGF-
b to immunoreactive TGF-b platelet-poor plasma samples
was incubated for 10min at room temperature with 1 N
HCl and then the sample was neutralized with a solution
made of 1.2 N NaOH/0.5 M HEPES for another 10 minutes
before the determination was performed. Commercially
available kits, also from R & D systems were used to deter-
mine antithyroglobulin (TG), antithyroid peroxidase (TPO),
anticardiolipin, antiglomerular basement membrane (GBM)
and anticyclic citrullinated peptide (CCP) antibodies. The
plates were read in a Multiskan Ascent (Thermolab systems,
Maltham, MA, USA) microplate reader using a 450 and
490nm ﬁlters. Results represent the mean of duplicates.
Hormone determination (TsH, T3, and free T4) and
liver function tests (ALT, AST, Albumin, Immunoglobulin)
were performed in the laboratory of the hospital. Subclinical
hypothyroidism was deﬁned as a TsH value of ≥4p g / m lwi t h
normal T3 and T4 values.
The results of all these evaluations in the control group
were within the established normal values determined in
our laboratory (0.25–4.0μUI/ml for TsH; 0.6–1.9ng/ml for
T3; 0.7–1.8ng/dl for free T4; 2–40UI/ml for AST and 2–
40UI/ml for ALT). The results obtained in the control
samples for the diﬀerent cytokines were 6.8 ± 2.7pg/ml for
IL-2; 4.9 ± 1.4pg/ml for IL-10; 52.7 ± 8.1pg/ml for IL-12;
6.75 ± 1.14pg/ml for IL-17, and 398 ± 271pg/ml for TGF-
b1). The normal value for anti-TG is 0–34IU/ml, 0-12IU/ml
for anti-TPO, >10IU/ml for anti-cardiolipin, and 0–7IU/ml
for anti-GBM and anti-CCP antibodies.
2.3. Statistical Analysis. Data is expressed as mean ± stan-
dard deviation of the mean. Diﬀerences between groups
were evaluated by Student’s t test, conﬁdence interval at the
95% value, Tukey test and Kruskal-Wallis one way analysis




The mean age of male patients was 45.7 years old whereas
that of the females was 51.8 years old. The predominant
HCV genotype was 1b (42 patients) followed by 1a (18
patients), 2b (17 patients), 2a (9 patients), and one patient
with genotype 4. Table 1 shows the clinic-serological param-
eters of all the patients. Seventy percent of the patients
with elevated TsH (6.45 ± 2.21μIU/ml) (group A) were
females; the percentage of female patients in the group
with normal TsH values (2.58 ± 0.95μUI/ml) (group B)
was similar (71%). The diﬀerence in TsH values between
both groups was highly signiﬁcant (P< .0001) as well as
between group A and control group (P< .001; according
to the all pairwise multiple comparison procedures-Holm-
Sidak method). There were no statistical diﬀerences in TsH
values related to gender (5.82 ± 1.73μUI/ml for males
and 6.71 ± 2.40μUI/ml for females in group A versus
2.26 ± 0.76μUI/ml for males and 2.68 ± 0.99μUI/ml for
females, in group B). Similarly there were no statistical
signiﬁcant diﬀerences between both groups in relation to
viral load. Although the values of the following markers were
statistically diﬀerent from those of the control group, thereHepatitis Research and Treatment 3
were no statistical signiﬁcant diﬀerences between group A
and group B results in relation to AST, ALT, T3, and free
T4.
Eight group A patients had elevated anti-TG antibodies
(41%). Six of those also had elevated anti-TPO antibodies
(33%). One patient with normal anti-TG, anti-TPO, and
anti-CCPvalueshadelevatedanti-GBMandanti-cardiolipin
antibodies. This patient had consistently low platelet counts
but had no history of miscarriage or deep vein thrombosis.
None of the anti-TPO nor anti-TG positive patients in
group A had signs or symptoms of Hashimoto’s thyroiditis.
The percentage of autoantibodies in group B was 33% for
anti-TG antibodies, and 7% for anti-TPO. None of the
patients in group B had elevated values of anti-GBM or anti-
CCP, and only one had elevated anti-cardiolipin antibodies.
Interestingly, the latter patient was also positive for anti-
TPO antibodies and had deep vein thrombosis of the lower
extremities.
In relation to the cytokines it was interesting to observe
that although the concentrations in HCV+ patients were
signiﬁcantlyhigherthanthosefoundinthecontrolgroupfor
all the cytokines, the intergroup diﬀerences (group A indi-
viduals versus group B) for IL-10 (14.83 ± 2.98pg/ml versus
15.27 ±1.70pg/ml)andIL-12(271.59 ±196.43pg/mlversus
221.13 ± 101.60pg/ml) were not statistically signiﬁcant.
The cytokines that showed a highly statistically signiﬁcant
diﬀerence between group A and group B patients were: IL-
2, IL-17, and TGF-b (Table 1). The Kruskal-Wallis analysis
of variance at the 0.05 level of signiﬁcance for IL-2 showed
a median value of 611pg/mL for group A, 195pg/mL for
group B, and 7.36pg/mL for the control group (P<.001);
the signiﬁcance of these diﬀerences between groups A and B
with the control was conﬁrmed by the Tukey test (P<.05).
As far as IL-17 was concerned, the Kruskal-Wallis analysis
of variance showed a median value of 19.4pg/mL for group
A, 18.5pg/mL for group B, and 8.9pg/mL for the control
group (P<.001); similarly to IL-2, IL-17 results were also
conﬁrmed by the Tukey test. There were no diﬀerences
in IL-17 concentration in both groups in relation to the
viral genotype. Finally, TGF-b values passed the normality
test and the one way analysis of variance demonstrated
a signiﬁcant diﬀerence between groups A and B with the
controlgroup(P<.001)butnotbetweengroupAandgroup
B. It was interesting to observe that TGF-b concentration
in group A patients was 38% below that of group B
patients.
4. Discussion
HCV infection has been related to various autoimmune
disorders including thyroid dysfunction [1–4] and papil-
lary thyroid cancer [15]. Patients with HCV-related mixed
cryoglobulinemia also show thyroid dysfunction [3]. In
summary, the presence of hypothyroidism in chronically
HCV-infectedindividuals,eitherundertreatmentornot,has
been well documented [1, 16, 17]. One interesting obser-
vation was the high percentage of HCV-infected patients
having hypothyroidism (23%) versus an average 12% cited
in the literature; this could be secondary to the signiﬁ-
cantly higher frequency of thyroid microsomal antibodies
in Mexican women in comparison with Caucasian or black
women [18] thus representing a higher predisposition to
autoimmunityagainstthyroidgland.Wefoundautoimmune
thyroid involvement as judged from serum auto-antibodies
and Tsh values in 20 of the 87 patients that we analyzed. The
percentage of individuals in the subclinical hypothyroidism
group with autoantibodies was signiﬁcantly higher than
the percentage found in normothyroid HCV+ patients
and control. None of our patients had manifestations of
Hashimoto’s disease and only one of the female patients in
the hypothyroid group, had a pattern compatible with an
antiphospholipids syndrome, an association found in 20%
of HCV-infected patients [19]. The percentage of females
with autoimmune disease in our study (70%) is identical
to that found in a multicenter international study [20, 21].
Nevertheless, it has recently been suggested that the presence
of autoantibodies in HCV-infected patients do not appear to
beofclinicalimportance[22].Onepatientineachgrouphad
elevatedanticardiolipinantibodiesbutnoneofthemsuﬀered
stroke, although the patient with deep vein thrombosis is a
strongcandidate.Thisassociationhasalreadybeendescribed
[23].
The thyroid dysfunction in HCV-infected patients has
been associated to interleukin 2 [24–26], a cytokine secreted
primarily by Th1 cells. Patients with non-HCV-related
diseases being treated with high doses of IL-2 also develop
thyroid dysfunction [27, 28]. The increased interleukin 2
serum concentration determined in our non-IL-2 or IFN-
treated HCV+ hypothyroid patients, corroborates the above
mentioned ﬁndings. Interleukin 2 is known to expand Th17
cells in some autoimmune diseases [29].
A key cytokine for IL-2 production and Th1 cell diﬀeren-
tiation is IL-12 [30, 31]. Although the core protein of HCV
seems to have a suppressive action on IL-12 production at
the transcriptional level [32], our results showed that the
concentration of IL-12 was similar in both of our HCV-
infected groups, but considerably higher than the control
group. This suggests that hypothyroidism was not related to
interleukin-2 despite the fact that transgenic mice with IL-
12 serum concentrations in the 150 pg/ml range develop a
moderate primary hypothyroidism [33]. IL-12 is responsible
for inducing a Th17 response [5, 34]
TheTh17responseischaracterizedbyaserumincreasein
interleukin-17A, commonly known as IL-17. This cytokine,
secreted by the CD4+ T cells known as Th17, is also secreted
by some CD8+ T cells, NKT, alpha-beta or gamma-delta T
cells,eosinophils,neutrophils,andmonocytes[35–37].Th17
cells are mainly linked to autoimmune diseases, namely,
multiple sclerosis, inﬂammatory bowel disease, rheumatoid
arthritis, Lyme disease, psoriasis, and uveitis [29, 38]. Of
the ﬁve diﬀerent IL-17 receptors (A to E), IL-17 only
bind to IL-17RA and C [35, 39]. The pituitary gland and
the thyroid, in contrast to hepatocytes, express IL-17RC
[40]. The regulation of Th17 cells is basically mediated
by CD4+CD25+FoxP3+ T reg cells which are capable of
inducing anergy towards self- and alloantigens, thus playing
an important role in autoimmunity [41–43]. Nevertheless,4 Hepatitis Research and Treatment
Table 1: Clinicoserological ﬁndings in hypo- and normothyroidism HCV patients.
Group A (n = 20) Group B (n = 67) Control (n = 40) P value
Females/males 14/6 48/19 20/20 —
Age, mean ±SD (years) 49.8 ± 9.7 49.8 ± 12.2 51.2 ± 14.9 NS
HCV genotype
11 2 4 5 0 —
27 2 1 0 —
4 1—
V i r a ll o a dH C VR N A( <50IU/mL) 489,731 ± 381,451 399,129 ± 319,863 Negative NS
ALT (IU/mL) 99.75 ± 65.58 81.23 ± 55.38 25 ± 1.62 NS
AST (IU/mL) 81.37 ± 54.31 72.28 ± 54.33 32 ± 1.33 NS
Platelets (k/μL) 162 ± 73.3 206.6 ± 85.1 309 ± 95 NS
Albumine (g/dL) 4 ± 0.48 3.9 ± 0.8 4.1 ± 0.4 NS
TSH (μIU/mL)
Total 6.45 ± 2.21 2.58 ± 0.95
Males 5.82 ± 1.73 2.26 ± 0.76 2.6 ± 1.1 < .0001
Females 6.71 ± 2.40 2.68 ± 0.99
T3 (ng/mL) 1.4 ± 0.9 1.51± 0.6 1.3 ± 0.5 NS
T4F(ng/dL) 1.18 ± 0.4 1.51 ± 0.6 0.9 ± 0.3 NS
Anti-thyroperoxidase antibody (AbTPO)∗ 33% 7% Negative < .001
Anti-thyroglobulin antibody (AbTg)∗ 41% 33% Negative < .01
Anticyclic Citrullinated Peptides antibody (CCP) Negative Negative Negative —
Glomerular Basement Membrane (GBM) Negative Negative Negative —
Cardiolipin Negative Negative Negative
IL-2 (pg/mL) 643.07 ± 572.66∗∗ 292.89 ± 335.91 6.8 ± 2.7 < .0009
IL-10 (pg/mL) 14.83 ± 2.98 15.27 ± 1.70 4.9 ± 1.4 NS
IL-12 (pg/mL) 271.59 ± 2.98 221.13 ± 101.60 52.7 ± 8.1 NS
IL-17 (pg/mL) 25.88 ± 23.14∗∗ 14.60 ± 7.83 6.75 ± 1.14 < .001
TGF-β (pg/mL) 618.97 ± 221.89∗∗ 850.14 ± 415.64 398 ± 271 .019
Group A are the hypothyroid HCV+ patients whereas group B are the normothyroid HCV+ patients.
∗Percentage of patients with values above the normal range.
∗∗P<. 0 1b e t w e e ng r o u pAa n dg r o u pB .
a new regulatory mechanism mediated by IL-10 and TGF-
b, both of which suppress IL-17 production [11, 12], has
been suggested [44]. Our hypothyroid patients had similar
amounts of IL-10 than the normo thyroid group but lower
TGF-b serum concentration. Therefore, the only abnormal-
ity that could explain the high IL-17 serum concentration
and the thyroid dysfunction was related to alterations in
the FoxP3+ Treg cells, probably through enhanced Stat3
phosphorylation [36, 45]. Nevertheless, recent evidence
shows that TGF-beta orchestrates Th17 cell diﬀerentiation
in a concentration-dependent manner. Low TGF-b concen-
trations favors Th17 cell diﬀerentiation whereas high TGF-b
concentrations favors Foxp3+ Treg cell diﬀerentiation [43].
The former is accompanied by high levels of IL-17, as we
observed in our hypothyroid patients, whereas the latter is
accompanied by a tighter regulation of IL-17 secretion, as
we observed in our normothyroid patients. Despite TGF-b
apparent importance, Th17 diﬀerentiation depends basically
on the presence of IL-1 and IL-6 [46]. It has recently
been shown that the proportion of peripheral Th17 cells in
patients with autoimmune thyroid disease is higher than in
control subjects [47].
Although there is evidence showing that IL-2 can
inhibit human Th17 cell diﬀerentiation through a STAT-
5 mediated pathway and enhanced TGF-b-induced FoxP3
expression [48, 49] ,ar e c e n tr e p o r tb yD e k n u y d te ta l .[ 50]
show that CD4+CD25+ FOXP3+ T regulatory cells in the
presence of IL-2, in an inﬂammatory microenvironment,
can be converted into proinﬂammatory Th17 cells. This
could explain the link between inﬂammation, high IL-2 and
IL-17 concentrations, and autoimmunity in our patients.
Interleukin 17 is also involved in human alcoholic liver
disease,anentitythatsharessomefeatureswithautoimmune
diseases [51].
The viral load in our patients could be deﬁnitively
considered low and such viral loads have been linked with
the development of auto antibodies due to the lowering of
the B cell activation threshold or by inducing self-reactivity
through a mechanism of molecular mimicry [52, 53].
5. Conclusions
We believe that our results point towards an abnormality
in the T regulatory cells, induced by the hepatitis C virus.Hepatitis Research and Treatment 5
The fact that not all the HCV-infected patients develop an
full blown autoimmune disease suggests that there are many
individual variations that go beyond the viral load, viral
genotype, presence of auto antibodies or liver biochemical
alterations. We must not forget that the HCV does replicate
within the thyroid tissue [54] and that the evolution of the
HCV infection is related to distinct immune cell cytokine
expression proﬁles. Recently it has been postulated that a
Th1cell mediated immune response underpins the associa-
tion of chronic HCV infection with endocrine disease [55],
our results suggest that a Th17 immune response should also
be considered.
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